An observational post-approval safety study of golimumab in treatment of polyarticular Juvenile Idiopathic Arthritis (pJIA) using the German Biologics JIA Registry (BiKeR)

First published: 30/01/2018 Last updated: 09/10/2025





Administrative details

EU PAS number	
EUPAS20781	
Study ID	
47271	
DARWIN EU® study	
No	
Study countries	
Germany	

Study description

Simponi® (golimumab, GLM) received European marketing authorization for the treatment of polyarticular juvenile idiopathic arthritis (pJIA) on 24 June 2016. In connection with the approval in this indication, the Sponsor is committed to conduct a required postauthorization safety study (PASS) to monitor long-term safety of GLM in the treatment of pJIA in regular clinical practice setting. This is an observational PASS and will monitor safety and effectiveness of GLM use in the treatment of pJIA in usual clinical practice using data from the German Biologics JIA Registry (Biologika in der Kinderrheumatologie, BiKeR). The study will comprise four study cohorts: GLM cohort, contemporary antitumor necrosis factor (anti-TNF) control cohort (including adalimumab ADA, etanercept ETA, or their biosimilars when available), contemporary methotrexate (MTX) control cohort, and historic anti-TNF control cohort (ADA or ETA).

The primary objectives are to describe the baseline clinical and demographic characteristics of the four study cohorts, to evaluate long-term safety of GLM in treatment of pJIA, and to compare the risks of primary safety endpoints in GLM cohort with those in contemporary anti-TNF cohort (primary comparison) and with those in contemporary MTX cohort (secondary comparison), adjusted for baseline characteristics.

The study is transferred from Merck Sharp & Dohme to Janssen Pharmaceutica NV

Study status

Ongoing

Research institutions and networks

Institutions

Biologika in der Kinderrheumatologie-Register (BIKER) at the Asklepios Klinik Sankt Augustin Germany First published: 01/02/2024

Institution

Hospital/Clinic/Other health care facility

Contact details

Study institution contact

Last updated: 01/02/2024

Suzan Esslinger RA-RNDUS-ClnclTrlsEU@its.jnj.com

Study contact

RA-RNDUS-ClnclTrlsEU@its.jnj.com

Primary lead investigator

Gerd Horneff

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual: 03/05/2017

Study start date

Planned: 31/01/2018

Actual: 31/01/2018

Data analysis start date

Planned: 01/12/2026

Date of final study report

Planned: 30/06/2027

Sources of funding

Pharmaceutical company and other private sector

More details on funding

Janssen Pharmaceutica NV

Study protocol

8259-050-v1 final-redaction.pdf (518.35 KB)

REDACTED_NIS-Protocol-Amend-PCSIMMA0237-1487260_1694092.pdf (1.3 MB)
REDACTED_NIS-Protocol-Amend-PCSIMMA0237-1487260_1694092.pdf (1.3 MB)
MK-8259-050-02-V2-JANSSEN-Prot_Final Redaction.pdf (683.14 KB)

Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Other study registration identification numbers and links

PCSIMMA0237

MK-8259-050

Methodological aspects

Study type

Study type list

Study topic:

Disease /health condition

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Safety study (incl. comparative)

Main study objective:

To evaluate long-term GLM safety in treatment of pJIA by describing risk of primary safety endpoints for 4 cohorts: serious infections, malignancy, autoimmune processes, exposure during pregnancy, and to compare the risks in the GLM cohort vs. the comparator cohorts.

Study Design

Non-interventional study design

Cohort

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

GOLIMUMAB

Anatomical Therapeutic Chemical (ATC) code

(L04AB06) golimumab golimumab

Medical condition to be studied

Juvenile idiopathic arthritis

Population studied

Age groups

- Children (2 to < 12 years)
- Adolescents (12 to < 18 years)

Estimated number of subjects

3258

Study design details

Outcomes

Serious infections (including opportunistic infections, TB and hepatitis B reactivation), malignancy, autoimmune processes (including thyroiditis, autoimmune diabetes, uveitis, psoriasis, IBD, celiac disease, demyelinating disorders, as well as SLE), exposure during pregnancy.

Incidence of demyelinating disorders, serious depression including suicidality, PedACR 30/50/70/90 & JADAS-10 scores, treatment duration/discontinuation.

Data analysis plan

For primary safety endpoints, frequency/incidence rate will be calculated for each cohort. Subgroup analyses stratified by history of prior anti-TNF use will be done if data permit.

For secondary safety endpoints, frequency/incidence rate will be calculated for the GLM cohort, and two contemporary comparator cohorts. For historic anti-TNF cohort, frequencies/incidence rates will be calculated only for those secondary endpoints systematically collected during the historic observation period.

For GLM cohort, treatment response will be described at months 3, 6, 12, and 24 compared to baseline.

For GLM cohort, treatment duration and reasons for GLM discontinuation will be described.

Comparative analyses between GLM and two contemporary comparator cohorts may be done for primary safety outcomes adjusting for potential confounders in the final report.

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data source(s)

Biologika in der Kinderrheumatologie

Data sources (types)

Disease registry

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No